PTCT – PTC Therapeutics Inc
PTCT — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
12.21
Margin Of Safety %
Put/Call OI Ratio
0.14
EPS Next Q Diff
-0.67
EPS Last/This Y
-6.98
EPS This/Next Y
0.9
Price
73.32
Target Price
97.86
Analyst Recom
1.87
Performance Q
13.68
Upside
-128.2%
Beta
0.55
Ticker: PTCT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | PTCT | 81.35 | 0.14 | 0.09 | 13084 |
| 2026-07-14 | PTCT | 78.07 | 0.14 | 2.15 | 13260 |
| 2026-07-15 | PTCT | 78.84 | 0.14 | 0.13 | 13685 |
| 2026-07-16 | PTCT | 78.52 | 0.14 | 0.00 | 13870 |
| 2026-07-17 | PTCT | 78.53 | 0.14 | 0.25 | 13870 |
| 2026-07-20 | PTCT | 78.03 | 0.14 | 0.00 | 13718 |
| 2026-07-21 | PTCT | 78.45 | 0.14 | 0.00 | 13828 |
| 2026-07-22 | PTCT | 78.41 | 0.14 | 0.00 | 13850 |
| 2026-07-23 | PTCT | 78.45 | 0.14 | 0.00 | 13885 |
| 2026-07-24 | PTCT | 76.82 | 0.13 | 0.42 | 14091 |
| 2026-07-27 | PTCT | 75.76 | 0.13 | 0.40 | 14285 |
| 2026-07-28 | PTCT | 75.41 | 0.13 | 0.02 | 14356 |
| 2026-07-29 | PTCT | 74.48 | 0.13 | 0.31 | 15515 |
| 2026-07-30 | PTCT | 75.59 | 0.13 | 0.24 | 15717 |
| 2026-07-31 | PTCT | 67.93 | 0.13 | 0.43 | 15900 |
| 2026-08-03 | PTCT | 68.11 | 0.12 | 0.75 | 16716 |
| 2026-08-04 | PTCT | 69.08 | 0.12 | 0.07 | 16721 |
| 2026-08-05 | PTCT | 69.23 | 0.12 | 1.05 | 16726 |
| 2026-08-07 | PTCT | 73.34 | 0.14 | 0.10 | 17337 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | PTCT | 81.34 | 145.4 | - | 1.49 |
| 2026-07-14 | PTCT | 78.04 | 145.4 | - | 1.49 |
| 2026-07-15 | PTCT | 78.84 | 145.4 | - | 1.49 |
| 2026-07-16 | PTCT | 78.57 | 145.4 | - | 1.49 |
| 2026-07-17 | PTCT | 78.52 | 145.4 | - | 1.49 |
| 2026-07-20 | PTCT | 78.04 | 145.4 | - | 1.49 |
| 2026-07-21 | PTCT | 78.46 | 145.4 | - | 1.49 |
| 2026-07-22 | PTCT | 78.37 | 145.4 | - | 1.49 |
| 2026-07-23 | PTCT | 78.46 | 145.4 | - | 1.49 |
| 2026-07-24 | PTCT | 76.79 | 145.4 | - | 1.49 |
| 2026-07-27 | PTCT | 75.82 | 141.0 | - | 1.49 |
| 2026-07-28 | PTCT | 75.39 | 141.0 | - | 1.32 |
| 2026-07-29 | PTCT | 74.49 | 141.0 | - | 1.32 |
| 2026-07-30 | PTCT | 75.61 | 141.0 | - | 1.32 |
| 2026-07-31 | PTCT | 67.93 | 141.0 | - | 1.32 |
| 2026-08-03 | PTCT | 68.05 | 155.5 | - | 1.32 |
| 2026-08-04 | PTCT | 68.05 | 155.5 | - | 1.32 |
| 2026-08-05 | PTCT | 69.20 | 19.7 | - | 1.49 |
| 2026-08-06 | PTCT | 70.86 | 19.7 | - | 1.49 |
| 2026-08-07 | PTCT | 73.32 | 65.0 | - | 1.60 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | PTCT | -9.84 | 3.09 | 21.61 |
| 2026-07-14 | PTCT | -10.36 | 3.09 | 21.61 |
| 2026-07-15 | PTCT | -10.36 | 3.09 | 21.61 |
| 2026-07-16 | PTCT | -10.36 | 3.09 | 21.61 |
| 2026-07-17 | PTCT | -10.46 | 3.09 | 21.61 |
| 2026-07-20 | PTCT | -10.46 | 3.12 | 21.61 |
| 2026-07-21 | PTCT | -10.46 | 3.12 | 21.61 |
| 2026-07-22 | PTCT | -10.46 | 3.12 | 21.61 |
| 2026-07-23 | PTCT | -10.44 | 3.12 | 21.61 |
| 2026-07-24 | PTCT | -10.44 | 3.12 | 21.61 |
| 2026-07-27 | PTCT | -10.44 | 2.92 | 12.27 |
| 2026-07-28 | PTCT | -10.44 | 2.92 | 12.27 |
| 2026-07-29 | PTCT | -10.44 | 2.92 | 12.27 |
| 2026-07-30 | PTCT | -10.44 | 2.92 | 12.27 |
| 2026-07-31 | PTCT | -10.44 | 2.92 | 12.27 |
| 2026-08-03 | PTCT | -10.38 | 4.32 | 12.20 |
| 2026-08-04 | PTCT | -10.38 | 4.32 | 12.20 |
| 2026-08-05 | PTCT | -10.38 | 4.32 | 12.20 |
| 2026-08-06 | PTCT | -10.38 | 4.32 | 12.20 |
| 2026-08-07 | PTCT | -10.50 | 4.32 | 12.21 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.92
Avg. EPS Est. Current Quarter
0.31
Avg. EPS Est. Next Quarter
0.25
Insider Transactions
-10.5
Institutional Transactions
4.32
Beta
0.55
Average Sales Estimate Current Quarter
309
Average Sales Estimate Next Quarter
320
Fair Value
Quality Score
74
Growth Score
44
Sentiment Score
44
Actual DrawDown %
19.3
Max Drawdown 5-Year %
-69.4
Target Price
97.86
P/E
Forward P/E
26.54
PEG
P/S
6.07
P/B
P/Free Cash Flow
EPS
-0.59
Average EPS Est. Cur. Y
1.6
EPS Next Y. (Est.)
2.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-3.8
Relative Volume
0.52
Return on Equity vs Sector %
-4.1
Return on Equity vs Industry %
12
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.28
EBIT Estimation
◆
PTCT
Healthcare
$73.31
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
44.7
Range 1M
31.3%
Sup Dist
5.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-81.6%
EPS NY
93%
52W%
62.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+23.4% upside
Upside
+23.4%
Quality
74
PTCT — P/E HistoricalBiotechnology
PTC Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 991
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
PTCT
Latest News
—
Caricamento notizie per PTCT…
stock quote shares PTCT – PTC Therapeutics Inc Stock Price stock today
news today PTCT – PTC Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTCT – PTC Therapeutics Inc yahoo finance google finance
stock history PTCT – PTC Therapeutics Inc invest stock market
stock prices PTCT premarket after hours
ticker PTCT fair value insiders trading